41°FOvercastFull Forecast

AbbVie 2Q profit climbs 2.8 percent

Published: Friday, July 25, 2014 5:22 p.m. CST

NORTH CHICAGO – Drugmaker AbbVie Inc.’s second-quarter profit increased nearly 3 percent and beat analysts’ expectations, as sales soared for the world’s top-selling drug, Humira.

The North Chicago company said Friday that earnings increased to $1.1 billion, or 68 cents per share, from $1.07 billion, or 66 cents per share, in the same quarter last year.

Earnings, adjusted for non-recurring costs and amortization costs, came to 82 cents per share. Analysts expected, on average, earnings of 76 cents per share, according to FactSet.

Revenue climbed 5 percent to $4.93 billion, which also trumped average analyst expectations of $4.7 billion.

Sales of the anti-inflammatory drug Humira jumped 26 percent to $3.29 billion in the quarter.

The data firm IMS Health ranks Humira, which brought in more than $10 billion in revenue last year, as the world’s best-selling drug.

AbbVie announced last week that it had reached a deal worth about $55 billion to combine with fellow drugmaker Shire Plc. and become the latest U.S. company to seek an overseas haven from tax rates back home. The drugmakers plan to create a new company that is incorporated on the British island of Jersey, where Shire is incorporated. But the new company will be controlled by AbbVie shareholders.

Get breaking and town-specific news sent to your phone. Sign up for text alerts from the Northwest Herald.

Copyright 2017 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Reader Poll

Are you giving up anything for Lent?